James F Dawkins1, Yu-Feng Hu2, Jackelyn Valle1, Lizbeth Sanchez1, Yong Zheng1, Eduardo Marbán1, Eugenio Cingolani3. 1. Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California. 2. Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California; Division of Cardiology, Department of Internal Medicine, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan. 3. Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California. Electronic address: eugenio.cingolani@csmc.edu.
Abstract
BACKGROUND: Right ventricular (RV) pacing-induced cardiomyopathy (PICM) occurs in ∼30% of patients with RV leads. This study evaluated the long-term effects of restoring antegrade conduction with a biological pacemaker in a porcine model of RV PICM. OBJECTIVES: The goal of this study was to determine if antegrade biological pacing can attenuate RV PICM. METHODS: In pigs with complete atrioventricular (AV) block, transcription factor T-box 18 (TBX18) was injected into the His bundle region in either of 2 experimental protocols: protocol A sought to prevent PICM, and protocol B sought to reverse PICM. In protocol A, we injected adenoviral vectors expressing TBX18 (or the reporter construct green fluorescent protein) after AV node ablation, and observed the animals for 8 weeks. In protocol B, PICM was established by using AV node ablation and 4 weeks of electronic RV pacing, at which point TBX18 was injected into the His bundle region. RESULTS: In protocol A, TBX18 biological pacing led to superior chronotropic support (62.4 ± 3 beats/min vs. 50.4 ± 0.4 beats/min; p = 0.01), lower backup pacemaker utilization (45 ± 2.6% vs. 94.6 ± 1.4%; p = 0.001), and greater ejection fraction (58.5 ± 1.3% vs. 46.7 ± 2%; p = 0.001). In protocol B, full-blown RV PICM was evident 4 weeks after complete AV block in both groups; subsequent intervention led to higher mean heart rate (56 ± 2 beats/min vs. 50.1 ± 0.4 beats/min; p = 0.05), less backup pacemaker utilization (53 ± 8.2% vs. 95 ± 1.6%; p = 0.003), and a greater ejection fraction (61.7 ± 1.3% vs. 49 ± 1.6%; p = 0.0003) in TBX18-injected animals versus control animals. CONCLUSIONS: In a preclinical model, pacemaker-induced cardiomyopathy can be prevented, and reversed, by restoring antegrade conduction with TBX18 biological pacing.
BACKGROUND: Right ventricular (RV) pacing-induced cardiomyopathy (PICM) occurs in ∼30% of patients with RV leads. This study evaluated the long-term effects of restoring antegrade conduction with a biological pacemaker in a porcine model of RV PICM. OBJECTIVES: The goal of this study was to determine if antegrade biological pacing can attenuate RV PICM. METHODS: In pigs with complete atrioventricular (AV) block, transcription factor T-box 18 (TBX18) was injected into the His bundle region in either of 2 experimental protocols: protocol A sought to prevent PICM, and protocol B sought to reverse PICM. In protocol A, we injected adenoviral vectors expressing TBX18 (or the reporter construct green fluorescent protein) after AV node ablation, and observed the animals for 8 weeks. In protocol B, PICM was established by using AV node ablation and 4 weeks of electronic RV pacing, at which point TBX18 was injected into the His bundle region. RESULTS: In protocol A, TBX18 biological pacing led to superior chronotropic support (62.4 ± 3 beats/min vs. 50.4 ± 0.4 beats/min; p = 0.01), lower backup pacemaker utilization (45 ± 2.6% vs. 94.6 ± 1.4%; p = 0.001), and greater ejection fraction (58.5 ± 1.3% vs. 46.7 ± 2%; p = 0.001). In protocol B, full-blown RV PICM was evident 4 weeks after complete AV block in both groups; subsequent intervention led to higher mean heart rate (56 ± 2 beats/min vs. 50.1 ± 0.4 beats/min; p = 0.05), less backup pacemaker utilization (53 ± 8.2% vs. 95 ± 1.6%; p = 0.003), and a greater ejection fraction (61.7 ± 1.3% vs. 49 ± 1.6%; p = 0.0003) in TBX18-injected animals versus control animals. CONCLUSIONS: In a preclinical model, pacemaker-induced cardiomyopathy can be prevented, and reversed, by restoring antegrade conduction with TBX18 biological pacing.
Authors: Mads B Kronborg; Peter T Mortensen; Steen H Poulsen; Jens C Gerdes; Henrik K Jensen; Jens C Nielsen Journal: Europace Date: 2014-02-07 Impact factor: 5.214
Authors: Fadi G Akar; Robert D Nass; Samuel Hahn; Eugenio Cingolani; Manish Shah; Geoffrey G Hesketh; Deborah DiSilvestre; Richard S Tunin; David A Kass; Gordon F Tomaselli Journal: Am J Physiol Heart Circ Physiol Date: 2007-04-13 Impact factor: 4.733
Authors: Eugene S Chung; Angel R Leon; Luigi Tavazzi; Jing-Ping Sun; Petros Nihoyannopoulos; John Merlino; William T Abraham; Stefano Ghio; Christophe Leclercq; Jeroen J Bax; Cheuk-Man Yu; John Gorcsan; Martin St John Sutton; Johan De Sutter; Jaime Murillo Journal: Circulation Date: 2008-05-05 Impact factor: 29.690
Authors: Bruce L Wilkoff; James R Cook; Andrew E Epstein; H Leon Greene; Alfred P Hallstrom; Henry Hsia; Steven P Kutalek; Arjun Sharma Journal: JAMA Date: 2002-12-25 Impact factor: 56.272
Authors: Melad Farraha; Juntang Lu; Ivana Trivic; Michael A Barry; James Chong; Saurabh Kumar; Eddy Kizana Journal: PLoS One Date: 2020-02-10 Impact factor: 3.240